Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays

Mayo Clinic Proceedings

Volumn 81, Issue 12, 2006, Pages 1575-1578

  Katzmann, Jerry A ^a   Dispenzieri, Angela ^a   Kyle, Robert A ^a   Snyder, Melissa R ^a   Plevak, Matthew F ^a   Larson, Dirk R ^a   Abraham, Roshini S ^a   Lust, John A ^a   Melton III, L Joseph ^a   Rajkumar, S Vincent ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENCE JONES PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; PARAPROTEIN;

ALGORITHM; ARTICLE; FREE LIGHT CHAIN ASSAY; HUMAN; IMMUNOASSAY; LIGHT CHAIN; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMA CELL DYSCRASIA; PLASMACYTOMA; PROTEIN ELECTROPHORESIS; QUANTITATIVE DIAGNOSIS; SERUM IMMUNOFIXATION; URINALYSIS;

EID: 33845334882     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.12.1575     Document Type: Article

References (12)

1. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.
2. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001;47:673-680.
3. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437-1444.
4. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001;97:2900-2902.
5. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122:78-84.
6. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet. 2003;361:489-491.
7. Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. Diagnostic performance of quantitative κ and λ free light chain assays in clinical practice. Clin Chem. 2005 May;51:878-881. Epub 2005 Mar 17.
8. Bradwell AR. Serum free light chain measurements move to center stage [editorial]. Clin Chem. 2005;51:805-807.
9. Hofmann W, Garbrecht M, Bradwell AR, Guder WG. A new concept for detection of Bence Jones proteinuria in patients with monoclonal gammopathy. Clin Lab. 2004;50:181-185.
10. Hill PG, Forsyth JM, Rai B, Mayne S. Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies. Clin Chem. 2006 Sep;52:1743-1748. Epub 2006 Jul 20.
11. Bakshi NA, Gulbranson R, Garstka D, Bradwell AR, Keren DF. Serum free light chain (FLC) measurement can aid capillary zone electrophoresis in detecting subtle FLC-producing M proteins. Am J Clin Pathol. 2005;124:214-218.
12. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005 Aug;106:812-817. Epub 2005 Apr 26.